GOSS
Gossamer Bio, Inc.
Key Financials
EPS (Diluted)
$-0.75
↓ 200.0%
Cash & Equivalents
$37.7M
↓ 18.1%
Operating Cash Flow
$-171266000.00
↓ 4838.5%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 5/18/2026 | View on SEC |
| DEFA14A | 5/18/2026 | View on SEC |
| 8-K | 5/18/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| ARS | 4/24/2026 | View on SEC |
| DEFA14A | 4/24/2026 | View on SEC |
| DEF 14A | 4/24/2026 | View on SEC |
| 8-K | 4/9/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GOSS |
| Company Name | Gossamer Bio, Inc. |
| CIK | 1728117 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 684-1300 |